Related Experiment Video
Updated: Jul 3, 2026
07:53
Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
Published on: April 17, 2026
Targeted therapy for cancer using PARP inhibitors
Christopher J Lord1, Alan Ashworth
1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, UK. Chris.Lord@icr.ac.uk
Current Opinion in Pharmacology
|July 23, 2008
Summary
Poly (ADP-ribose) Polymerase (PARP) inhibitors show promise as cancer treatments, particularly for BRCA-mutated cancers, by exploiting synthetic lethality. Further research is needed to optimize their specificity and potency for clinical use.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly (ADP-ribose) Polymerase (PARP) enzymes are crucial for DNA repair.
- Small molecule PARP inhibitors are developed as chemotherapy sensitizers.
- PARP inhibition demonstrates selectivity for cancers with BRCA1/BRCA2 deficiencies.
Purpose of the Study:
- To explore the potential of PARP inhibitors in treating BRCA-mutated cancers.
- To investigate the synthetic lethal approach for cancer therapy.
- To address unanswered questions regarding PARP inhibitor specificity and potency.
Main Methods:
- Review of established roles of PARP in DNA repair.
- Analysis of studies demonstrating PARP inhibitor selectivity for BRCA deficiency.
- Examination of emerging mechanisms of cellular resistance to PARP inhibitors.
Main Results:
- PARP inhibitors show potential as a targeted therapy for BRCA-mutated cancers.
- This represents a clinically relevant application of synthetic lethality.
- Understanding resistance mechanisms is key to optimizing clinical application.
Conclusions:
- PARP inhibitors offer a promising synthetic lethal strategy for BRCA-mutated cancers.
- Further research is required to define optimal PARP inhibitor specificity and potency.
- Investigating resistance mechanisms will guide effective clinical use of PARP inhibitors.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...